The estimated Net Worth of Charles M Warden is at least $16.7 Milion dollars as of 15 June 2015. Mr. Warden owns over 320,000 units of Ocular Therapeutix Inc stock worth over $109,779 and over the last 10 years he sold OCUL stock worth over $16,434,000. In addition, he makes $139,518 as Independent Chairman of the Board at Ocular Therapeutix Inc.
Charles has made over 2 trades of the Ocular Therapeutix Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 320,000 units of OCUL stock worth $7,040,000 on 15 June 2015.
The largest trade he's ever made was selling 427,000 units of Ocular Therapeutix Inc stock on 10 June 2015 worth over $9,394,000. On average, Charles trades about 49,800 units every 0 days since 2014. As of 15 June 2015 he still owns at least 13,007 units of Ocular Therapeutix Inc stock.
You can see the complete history of Mr. Warden stock trades at the bottom of the page.
Charles M. Warden serves as Independent Chairman of the Board of the Company. Mr. Warden has served as a Managing Director at Versant Ventures since 2004. Prior to Versant, he was a General Partner at Schroder Ventures Life Sciences (now SV Life Sciences), where he worked from 1996 to 2004. Previously, Mr. Warden served as an associate with Boston Capital Ventures and as a consultant with Monitor Company. He serves or has served on the boards of numerous privately-held life sciences companies. Mr. Warden holds a B.A. in Economics and Classics from Beloit College and an M.B.A. from Harvard University.
As the Independent Chairman of the Board of Ocular Therapeutix Inc, the total compensation of Charles Warden at Ocular Therapeutix Inc is $139,518. There are 9 executives at Ocular Therapeutix Inc getting paid more, with Antony Mattessich having the highest compensation of $2,126,150.
Charles Warden is 51, he's been the Independent Chairman of the Board of Ocular Therapeutix Inc since 2019. There are 14 older and 2 younger executives at Ocular Therapeutix Inc. The oldest executive at Ocular Therapeutix Inc is Richard Lindstrom, 72, who is the Independent Director.
Charles's mailing address filed with the SEC is C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD, MA, 01730.
Over the last 10 years, insiders at Ocular Therapeutix Inc have traded over $73,512,800 worth of Ocular Therapeutix Inc stock and bought 6,361,550 units worth $38,632,070 . The most active insiders traders include Management Inc. Opaleye, Road Llc Summer oraz Venture Management Co. V, L.... On average, Ocular Therapeutix Inc executives and independent directors trade stock every 43 days with the average trade being worth of $999,228. The most recent stock trade was executed by Sanjay Nayak on 23 August 2024, trading 1,832 units of OCUL stock currently worth $16,525.
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
Ocular Therapeutix Inc executives and other stock owners filed with the SEC include: